These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30488197)

  • 1. Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters.
    Zabotina TN; Korotkova OV; Chertkova AI; Zakharova EN; Tabakov DV; Dzhgamadze NT; Savostikova MV; Artamonova EV; Khailenko VA; Kovalenko EI; Kadagidze ZG
    Bull Exp Biol Med; 2018 Dec; 166(2):241-244. PubMed ID: 30488197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
    Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
    Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.
    Zhu S; Lin J; Qiao G; Xu Y; Zou H
    Tumour Biol; 2015 Sep; 36(10):7907-13. PubMed ID: 25953262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.
    Leong PP; Mohammad R; Ibrahim N; Ithnin H; Abdullah M; Davis WC; Seow HF
    Immunol Lett; 2006 Feb; 102(2):229-36. PubMed ID: 16246429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients.
    Chan MS; Wang L; Felizola SJ; Ueno T; Toi M; Loo W; Chow LW; Suzuki T; Sasano H
    Int J Biol Markers; 2012 Dec; 27(4):e295-304. PubMed ID: 23280127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
    Liyanage UK; Moore TT; Joo HG; Tanaka Y; Herrmann V; Doherty G; Drebin JA; Strasberg SM; Eberlein TJ; Goedegebuure PS; Linehan DC
    J Immunol; 2002 Sep; 169(5):2756-61. PubMed ID: 12193750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lymphocyte activation markers in patients with ovarian cancer].
    Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
    Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
    Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
    Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.
    Grimm M; Feyen O; Hofmann H; Teriete P; Biegner T; Munz A; Reinert S
    Tumour Biol; 2016 Mar; 37(3):3807-16. PubMed ID: 26474587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status.
    Glajcar A; Szpor J; Hodorowicz-Zaniewska D; Tyrak KE; Okoń K
    Virchows Arch; 2019 Jul; 475(1):13-23. PubMed ID: 31016433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer.
    Chin Y; Janseens J; Vandepitte J; Vandenbrande J; Opdebeek L; Raus J
    Anticancer Res; 1992; 12(5):1463-6. PubMed ID: 1332579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis.
    Ziai J; Gilbert HN; Foreman O; Eastham-Anderson J; Chu F; Huseni M; Kim JM
    PLoS One; 2018; 13(1):e0190158. PubMed ID: 29320521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racial differences in CD8
    Abdou Y; Attwood K; Cheng TD; Yao S; Bandera EV; Zirpoli GR; Ondracek RP; Stein L; Bshara W; Khoury T; Ambrosone CB; Omilian AR
    Breast Cancer Res; 2020 Jun; 22(1):62. PubMed ID: 32517730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.
    Ali HR; Provenzano E; Dawson SJ; Blows FM; Liu B; Shah M; Earl HM; Poole CJ; Hiller L; Dunn JA; Bowden SJ; Twelves C; Bartlett JM; Mahmoud SM; Rakha E; Ellis IO; Liu S; Gao D; Nielsen TO; Pharoah PD; Caldas C
    Ann Oncol; 2014 Aug; 25(8):1536-43. PubMed ID: 24915873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer.
    Mani NL; Schalper KA; Hatzis C; Saglam O; Tavassoli F; Butler M; Chagpar AB; Pusztai L; Rimm DL
    Breast Cancer Res; 2016 Jul; 18(1):78. PubMed ID: 27473061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
    Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
    Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma.
    Walsh NM; Fleming KE; Hanly JG; Dakin Hache K; Doucette S; Ferrara G; Cerroni L
    Hum Pathol; 2016 Jun; 52():190-6. PubMed ID: 26980039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
    Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.
    Miyashita M; Sasano H; Tamaki K; Chan M; Hirakawa H; Suzuki A; Tada H; Watanabe G; Nemoto N; Nakagawa S; Ishida T; Ohuchi N
    Breast Cancer Res Treat; 2014 Dec; 148(3):525-34. PubMed ID: 25395319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.